Prothyrotropin-releasing hormone (pro-TRH) is initially cleaved by the prohormone convertase-1/3 (PC1/3) in the trans-Golgi network generating N- and C-terminal intermediate forms that are then packed into secretory vesicles. However, it is not known whether these peptides are differentially sorted within the secretory pathway. This is of key importance because the processing products of several prohormones fulfill different biological functions. Using AtT20 cells stably transfected with prepro-TRH cDNA, we found that two specific N- and C-terminal peptides were located in different vesicles. Furthermore, the C-terminal pro-TRH-derived peptides were more efficiently released in response to KCl and norepinephrine, a natural secretagogue of TRH. Similar sorting and secretion of N- and C-terminal peptides occurs in vivo. When we blocked the initial proteolytic processing by a mutagenic approach, the differential sorting and secretion of these peptides were prevented. In summary, our data show that pro-TRH-derived peptides are differentially sorted within the secretory pathway and that the initial cleavage in the trans-Golgi network is key to this process. This could be a common mechanism used by neuroendocrine cells to regulate independently the secretion of different bioactive peptides derived from the same gene product.

Neuroendocrine cells secrete proteins through two pathways. The first one, the regulated secretory pathway (RSP), stores peptides in secretory granules (SGs) and releases them under external stimulation in a Ca2+-dependent manner. The second one is the constitutive pathway, which does not store proteins in SGs but instead delivers cargo material in transient vesicles for immediate release. Sorting to the constitutive or regulated pathways begins in the trans-Golgi network (TGN) and/or immature SGs. The proteolytic processing of many prohormones by prohormone convertases-1/3 (PC1/3) also begins in the TGN. Prohormones initially cleaved in the TGN include prothyrotropin-releasing hormone (pro-TRH), prosomatostatin, pronoctrotin-releasing factor, and pro-opiomelanocortin. Although some cases are controversial, most likely in the immature SGs. Initial processing of pro-TRH by PC1/3 in the TGN generates two intermediate forms that are then packed into immature SGs. Pro-TRH is initially cleaved by PC1/3 in the TGN to generate two intermediate forms prior to packaging into immature SGs. The initial cleavage occurs at two mutually exclusive sites: one generates the 15-kDa and the 10-kDa intermediate peptides, and the alternative cleavage generates 9.5- and 16.5-kDa intermediate peptides. The 10- and 16.5-kDa C-terminal intermediate forms are further processed to generate shorter C-terminal peptides in the TGN, whereas the 15- and 9.5-kDa N-terminal intermediates appear to undergo processing in a post-TGN compartment, most likely in the immature SGs. Initial processing of pro-TRH by PC1/3 in the TGN is also important for downstream sorting events that result in storage of pro-TRH-derived peptides in mature SGs. A differential sorting may be critical for pro-TRH, given that, in addition to TRH, other potential bioactive products have been identified. For instance, pro-TRH-(178–199) peptide is increased in the hypothalamus of female rats undergoing suckling; this peptide releases prolactin, which acts directly on pituitary cells and indirectly via inhibition of dopaminergic neurons in the arcuate nucleus. Prepro-TRH-(83–106) peptide increases in the periaqueductal gray of rats experiencing morphine withdrawal.
Sorting and Secretion of Pro-TRH-derived Peptides

**EXPERIMENTAL PROCEDURES**

Antibodies and Materials—The antibody against the N-terminal prepro-TRH (25–51) sequence (LPEAAQEGAVTPDLP-GLENVQRPE) plus a tyrosine at the N-terminal end for labeling purposes, named anti-pYE27, and the antibody against the C-terminal prepro-TRH (239–255) sequence (KQSPQVPEP-WDKEPLEE) plus a tyrosine added at the N-terminal end, named anti-pYE17, were generated in rabbit and had been characterized previously in our laboratory (20, 21, 23). Anti-pYE27 antibody recognizes only prepro-TRH (25–50) peptide. Anti-pYE17 antibody can potentially recognize prepro-TRH (25–255), prepro-TRH (115–255), prepro-TRH (160–255), and prepro-TRH (208–255) peptides (Fig. 1). For electron microscopy studies, antibodies were protein G-purified using protein A/G-agarose from Santa Cruz Biotechnology (Santa Cruz, CA). Unless otherwise specified, all other chemicals and reagents were obtained from Sigma.

In Vitro Studies—AtT20 cells (D16v-F2 subclone; ATCC, Manassas, VA) stably transfected with wild type prepro-TRH or mutant PC1/3-block prepro-TRH cDNAs were generated as described previously (22). In PC1/3-block pro-TRH, basic residues of initial cleavage (prepro-TRH residues 107, 108, 113, 114, 152, 153, 158, and 159) were mutated to glycine residues, which avoid initial processing of the precursor in the TGN. Importantly, this mutated precursor can be processed in other cleavage sites later in the RSP (22). Cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with high glucose (4.5 g/liter), 30 mM sodium bicarbonate, 1 mM sodium pyruvate, 10% fetal bovine serum, and 0.1% penicillin/streptomycin (Invitrogen) at 37 °C and 5% CO2. For secretion studies, AtT20 cells were plated in 6-well plates. When cultures were 80% confluent, cells were washed with Hanks’ solution and incubated with basal Dulbecco’s modified Eagle’s medium (2 ml/well, lacking serum and with protease inhibitor mixture (AEBSF: pepstatin A, E64, bestatin, leupeptin, and aprotinin; catalog No. P8340)). After 1 h of incubation, basal medium was collected and replaced with basal, norepinephrine (NE; 50–500 nM)-, or KCl (56 mM)-containing medium (2 ml/well). The NE treatments were based on previous reports (27–29). After 1 h of incubation, stimulated medium was collected, and cells were scraped into cold PBS and pelleted by centrifugation. Cells were lysed by the addition of 500 μl of 2 N acetic acid with protease inhibitor mixture and heated to 95 °C for 10 min. Samples were then sonicated and centrifuged at 15,000 rpm at 4 °C for 30 min. Supernatants were collected, and protein concentrations were determined by Bradford assay (Coomassie protein assay reagent, Pierce). An equal amount of medium (200 μl) or cell extract (4 μg of protein) from each group was evaporated using an Appropriate Technical Resources, Inc. (Laurel, MD) −110 °C speed vacuum system and reconstituted in 1 ml of 0.1% trifluoroacetic acid solution for HPLC separation. Eluted fraction were then evaporated and reconstituted in buffer used for radioimmunoassay (RIA) analysis. Data form basal and KCl-stimulated release were used to calculate the sorting index (SI) as follows: the percentage of total (cell content plus medium) immunoreactive material secreted under nonstimulation condition (basal release) was subtracted from the percentage secreted under KCl stimulation (stimulated release); this value was then divided by the percentage of basal release (30). Samples were run in triplicate per condition in three independent experiments.

For immunoelectron microscopy studies, cells were plated in LabTeks. On the day of the experiment, cells were washed with Hanks’ solution and fixed for 1 h with Karnovsky’s fixative or 4% paraformaldehyde, 0.15% glutaraldehyde in PBS. Samples were dehydrated with ethanol up to 96% followed by infiltration with LR White acrylic resin, hard grade (London Resin Co.) and embedding under a layer of Aclar film (Electron Microscopy Sciences, Hatfield, PA). Using a Reichert UltraCut S ultramicrotome, thin sections were prepared and placed on 300-mesh uncoated nickel grids for immunogold labeling.
Sorting and Secretion of Pro-TRH-derived Peptides

Ex Vivo and in Vivo Studies—Male Sprague-Dawley rats (~250 g) were purchased from Charles River Laboratories, Inc. (Wilmington, MA). The Institutional Animal Care and Use Committee of Rhode Island Hospital/Brown University approved the experimental protocols and euthanasia procedures. Secretion studies were performed in hypothalamic explants. Brains were removed from decapitated rats, placed in a brain matrix (Kent Scientific Corp., Torrington, CT), and cut using optic chiasm as rostral limit and mammillary bodies as caudal limit. Hypothalamic sulci were used as lateral limits, and a 3-mm-thick slice was taken parallel to the base of the hypothalamus. Hypothalamic explants were maintained in a static incubation system using artificial cerebrospinal fluid (aCSF; 126 mM NaCl, 6 mM KCl, 0.09 mM MgSO₄, 1.4 mM CaCl₂, 0.09 mM Na₂HPO₄, 20 mM NaHCO₃, 5 mM glucose, and protease inhibitor mixture, pH 7.4) gassed with 95% O₂ and 5% CO₂. Explants was collected in acetic acid, and peptides were extracted as described above. Samples were loaded into HPLC (300 μl of aCSF, 20 μg of extracted protein) and fractions analyzed by RIA. For mass spectrometry, 80 fractions (0.5 ml each) were collected over the entire 40-min gradient. For inhibitor mixture, pH 7.4) gassed with 95% O₂ and 5% CO₂.

HPLC Fractionation—A ProStar gradient mode HPLC system equipped with a C18 reverse phase column (Microsorb MV 300-8, 250 × 4.6 mm; Varian Inc., Palo Alto, CA) was used to fractionate samples. For peptide elution, a linear gradient from 0 to 80% of B was used with the following mobile phases: 0.1% trifluoroacetic acid (A) and 90% acetonitrile/0.1% trifluoroacetic acid (B). The flow rate was 1 ml/min, and there were equilibration times used on either side of the gradient. Forty fractions (1 ml) were collected over the entire 40-min gradient. These fractions were then evaporated using a −110 °C speed vacuum system and reconstituted in 210 μl of the buffer used in RIAs. For mass spectrometry, 80 fractions (0.5 ml each) were collected to obtain more pure samples.

Mass Spectrometry—Immunoreactive HPLC fractions of medium samples of AtT20 cells expressing wild type pro-TRH were evaporated and reconstituted in water. One μl of each sample was spotted on a normal phase chip array (NP20, Ciphergen Biosystems, Fremont, CA) as described recently (18). A negative control experiment was done in parallel using the same HPLC separation approach and analyzing medium of untransfected AtT20 cells. Arrays were read using a Protein-Chip System, Series 4000 (Ciphergen Biosystems). Spectra of the sample and calibrated standards were generated in auto-mode using the appropriate laser power. Analyses of spectra were accomplished using Ciphergen Express software (version 3.0) (32).

Immunoelectron Microscopy (IEM)—To perform double-sided immunogold labeling, each side of the grid was labeled separately. Sections were blocked with bovine serum albumin and 2% normal goat serum and then incubated with anti-pYE17 antibody (1:50) overnight at 4 °C. Sections were then floated on droplets of 10-nm gold-labeled goat anti-rabbit antibody (Electron Microscopy Sciences/Aurion, Hatfield, PA) for 2 h. Grids were blotted and air-dried. A second label was carried out using anti-pYE27 antibody (1:50) on the opposite side of the grid, avoiding contact with the dry side. After rinsing, sections were incubated with a 25-nm gold-labeled goat anti-rabbit antibody. Following rinses, sections were lightly stained for contrast with aqueous 2% uranyl acetate for 10 min followed by water rinses. Some sections were used to perform controls in which one or both primary antibodies were omitted. Sections were examined using a Morgagni 268 transmission electron microscope, and images were collected with an AMT Advantage CCD camera system. This experiment was repeated on two independent occasions.

Quantitative Analysis of Immunogold Labeling—To perform quantitative analysis, grids were first scanned at low magnification, and then high magnification micrographs were acquired of areas selected on the basis of good overall morphology. Negative and positive vesicles were counted in: (i) 12 section of different cells expressing wild type pro-TRH, (ii) 16 section of different cells expressing PC1/3-block pro-TRH, and (iii) 20 section of the ME. Positive vesicles were considered those that had at least double electron density compared with the background and colloidal gold particles. Gold particles in a ratio of 20 nm outside of a vesicle were considered part of the vesicle based on the minimum theoretical lateral resolution (33). Positive vesicles were counted and organized in three categories: 1) positive for anti-pYE27 antibody; 2) positive for anti-pYE17 antibody; and 3) positive for both antibodies. The relationship was expressed as a percentage, representing the proportion of a particular positive vesicle compared with total number of positive vesicles observed per micrographs. For quantitative analysis, we counted: i) ~980 vesicles of AtT20 cells expressing wild type pro-TRH; ii) ~910 vesicles of AtT20 cells expressing PC1/3-block pro-TRH; and iii) ~600 vesicles of ME. To confirm that the results were not dependent on the size of gold particles, co-staining was also done by using 6- and 10-nm gold-labeled goat anti-rabbit antibodies and by “reverse” staining, shifting the secondary antibodies. All tested variants of the procedure gave similar results. However, the final percentages slightly changed (data not shown) in particular because of the well known higher labeling efficiency of the smaller gold probes (33). The quantitative data shown here was obtained from sections labeled first with anti-pYE17 and 10-nm gold-particles and then with anti-pYE27 and 25-nm gold-particles, because these different size gold particles are more clearly resolved. To...
determine the vesicle diameter we performed point-to-point measurements using Image Capture Engine software, version 5.4.2.271, from Advanced Microscopy Techniques, on the electron microscopic images. Measuring software was calibrated at all magnifications using a diffraction grating replica having \( \frac{0.463}{\mu m} \) per line (Ernest Fullam Inc., Clifton Park, NY). For quantitative analysis of vesicle diameter we used: i) 260 vesicles of AtT20 cells expressing wild type pro-TRH (12 sections of different cells); ii) 270 vesicles of AtT20 cells expressing PC1/3-block pro-TRH (16 sections of different cells); and iii) 190 vesicles of ME.

Radioimmunoassay—RIAs using anti-pYE27 and anti-pYE17 antibodies were developed in our laboratory and described earlier (19). Customized peptides described above were used as tracers and standards. Tracers were iodinated using the chloramine-T oxidation-reduction method followed by HPLC purification. All RIAs were performed in duplicate. Sensitivity measures of pYE27 and pYE17 RIAs were \( \sim 10 \) and \( \sim 5 \) fmol/tube, respectively. Intra- and interassay variability measures were 5–6 and 9–12%, respectively.

Results are presented as mean \( \pm \) S.E. Statistical significance was determined by analysis of variance followed by a post hoc Newman-Keuls test. Differences were considered significant at \( p < 0.05 \).

RESULTS

AtT20 Cells Expressing Pro-TRH Differentially Secrete and Store N- and C-terminal Pro-TRH-derived Peptides—To perform this study, we initially investigated the N- and C-terminal peptides produced in AtT20 cells stably transfected with prepro-TRH cDNA. Medium and cell content were collected and subjected to HPLC purification, and fractions were analyzed using pYE27 and pYE17 RIAs. Analysis of medium samples with pYE27 RIA revealed the presence of two peaks at fractions 21 and 23 (Fig. 2A) and one peak at fraction 23 in the cell content samples (Fig. 2B). Analysis with pYE17 RIA showed two peaks at fractions 21, 28, 23 in the medium and cell content samples; the largest peak was at fraction 28 in cell content, whereas in medium the largest peak was at fraction 21 (Fig. 2, C and D). For pYE17 RIA there was also a small peak in medium samples at fraction 4, most likely unspecific because it was unaffected by treatments (see below). The medium peaks identified with pYE27 and pYE17 RIAs were further analyzed by mass spectrometry. As a negative control we used medium from untransfected AtT20 cells. Analysis of the spectra for fraction 21 showed three peptides with the following molecular masses: 1775, 2192, and 2755 Da (Fig. 2E). Fraction 21 of the negative sample showed a peptide of 2192 Da, indicating that this is not a pro-TRH-derived peptide (Fig. 2F). Thus, the 1775 Da peptide most likely corresponds to pro-prepro-TRH-(241–255) (theoretical molecular mass of 1811 Da) and the 2755 Da peptide to a variant of the N-terminal prepro-TRH-(25–50) (theoretical molecular mass of 2759 Da). Analysis of the spectra for fraction 23 showed one peptide with a molecular mass of 2759 Da,
Sorting and Secretion of Pro-TRH-derived Peptides

**TABLE 1**

<table>
<thead>
<tr>
<th>Secretagogue</th>
<th>Pro-TRH-derived peptides in medium</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N-terminal</td>
<td>C-terminal</td>
</tr>
<tr>
<td>Basal</td>
<td>255.1 ± 13.9</td>
<td>160.0 ± 7.4</td>
</tr>
<tr>
<td>NE (50 nM)</td>
<td>423.3 ± 30.8</td>
<td>308.3 ± 40.9</td>
</tr>
<tr>
<td>NE (500 nM)</td>
<td>474.7 ± 56.7</td>
<td>472.3 ± 29.5</td>
</tr>
<tr>
<td>KCl (56 mM)</td>
<td>587.4 ± 36.9</td>
<td>642.4 ± 57.8</td>
</tr>
<tr>
<td>SI</td>
<td>1.08 ± 0.13</td>
<td>2.60 ± 0.23</td>
</tr>
</tbody>
</table>

* p < 0.05 vs. basal.

- The first two columns of values show peptides released after 1 h of treatment with the different secretagogues. They are expressed as the total fmol of N- or C-terminal pro-TRH-derived peptides per ml of medium. Both peptides were measured by RIA. SI was calculated as indicated in the text.

- NE increased the secretion of N-terminal peptides to 423.3 ± 30.8 and 474.7 ± 56.7 fmol/ml, respectively (p < 0.05 versus basal) and secretion of the C-terminal peptides to 308.3 ± 40.9 and 472.3 ± 29.5 fmol/ml, respectively (p < 0.05 versus basal). Calculation of -fold stimulation showed that NE induced more secretion of C- than N-terminal pro-TRH-derived peptides (Fig. 3). To determine the release of these peptides by an unspecific secretagogue, we employed high potassium stimulation. KCl (56 mM) increased the secretion of N- and C-terminal pro-TRH-derived peptides to 587.4 ± 36.9 and 642.4 ± 57.8 fmol/ml, respectively (p < 0.05 versus basal). As shown in Fig. 3, KCl-induced secretion was more significant for C-terminal than for N-terminal peptides (4.02- ± 0.36-fold versus 2.30- ± 0.14-fold, respectively, p < 0.05). To assess the regulated release of N- and C-terminal pro-TRH-derived peptides, we calculated the SI, which is a quantitative measure of how well regulated is the secretion of a given peptide (see “Experimental Procedures”). Low SI values indicate that peptides are secreted via the constitutive secretory pathway, and high SI values indicate that secretion is more regulated. SI parameter was higher for C-terminal than for N-terminal peptides (2.60 ± 0.23 versus 1.08 ± 0.13, respectively; Table 1, p < 0.05) suggesting that C-terminal pro-TRH-derived peptides are more efficiently sorted in SGs than N-terminal peptides.

**FIGURE 3.** NE and KCl differentially release N- versus C-terminal pro-TRH-derived peptides in stably transfected AtT20 cells. Cells were stimulated with increasing concentrations of NE (50–500 nM) or KCl (56 mM) for up to 1 h. After incubation, medium was processed for HPLC followed by pYE27 and pYE17 RIAs analysis. This figure represents the -fold stimulation for both peptides and for each secretagogue calculated as the total molar amount of peptide in stimulated media/molar amount of peptide in basal media. Data are presented as the mean ± S.E. or p < 0.05 versus own basal release. b, p < 0.05 versus -fold stimulation of N-terminal pro-TRH-derived peptide for the same stimulus.

which is most likely another variant of the N-terminal prepro-TRH-(25–50) (Fig. 2G). Analysis of the spectra for fraction 28 showed one peptide with a molecular mass of 5138 Da, likely corresponding to C-terminal prepro-TRH-(208–255), which has a theoretical molecular mass of 5141 Da (Fig. 2H). In the past, we used to call to this peptide the 5.4-kDa C-terminal pro-TRH (17). Fractions 28 and 23 showed no detectable peptides in the negative control (data not shown).

To address whether N- and C-terminal pro-TRH-derived peptides are stored differentially, we investigated their secretion rate in prepro-TRH stably transfected AtT20 cells. The results are expressed as the total number of moles of N- or C-terminal pro-TRH-derived peptides secreted per milliliter (summarized in Table 1) or as -fold simulation (Fig. 3). Under steady state conditions, cell content for the N-terminal peptide was higher than for the C-terminal counterpart (38.0 ± 2.4 versus 23.1 ± 0.4 fmol/mg of protein, respectively, p < 0.05), and the ratio between N- and C-terminal peptides was 1.64 ± 0.09. Basal secretion for N-terminal peptides was also higher than for C-terminal peptides (255.1 ± 13.9 versus 160.0 ± 7.4 fmol/ml, respectively, p < 0.05), and the ratio between N- and C-terminal peptides in medium was 1.59 ± 0.07. Fifty and 500 nM NE increased the secretion of N-terminal peptides to 423.3 ± 30.8 and 474.7 ± 56.7 fmol/ml, respectively (p < 0.05 versus basal) and secretion of the C-terminal peptides to 308.3 ± 40.9 and 472.3 ± 29.5 fmol/ml, respectively (p < 0.05 versus basal). Calculation of -fold stimulation showed that NE induced more secretion of C- than N-terminal pro-TRH-derived peptides (Fig. 3). To determine the release of these peptides by an unspecific secretagogue, we employed high potassium stimulation. KCl (56 mM) increased the secretion of N- and C-terminal pro-TRH-derived peptides to 587.4 ± 36.9 and 642.4 ± 57.8 fmol/ml, respectively (p < 0.05 versus basal). As shown in Fig. 3, KCl-induced secretion was more significant for C-terminal than for N-terminal peptides (4.02- ± 0.36-fold versus 2.30- ± 0.14-fold, respectively, p < 0.05). To assess the regulated release of N- and C-terminal pro-TRH-derived peptides, we calculated the SI, which is a quantitative measure of how well regulated is the secretion of a given peptide (see “Experimental Procedures”). Low SI values indicate that peptides are secreted via the constitutive secretory pathway, and high SI values indicate that secretion is more regulated. SI parameter was higher for C-terminal than for N-terminal peptides (2.60 ± 0.23 versus 1.08 ± 0.13, respectively; Table 1, p < 0.05) suggesting that C-terminal pro-TRH-derived peptides are more efficiently sorted in SGs than N-terminal peptides.

N- and C-terminal Pro-TRH-derived Peptides Are Located in Different Vesicles of AtT20 Cells Expressing Pro-TRH—We then hypothesized that the non-equimolar release of peptides could be because N- and C-terminal pro-TRH-derived peptides are located in different vesicles. To test this possibility, we used an IEM approach. Under Karnovsky’s fixative the ultrastructure of cells was well preserved, but antigenicity was destroyed (data not shown). Therefore, we used a 4% paraformaldehyde/0.15% glutaraldehyde solution that maintained antigenicity and allowed the accurate identification of vesicles (Fig. 4, A–D). AtT20 cells expressing wild type pro-TRH showed a total of 42.8 ± 8.2% positive vesicles/cell/section. Positive vesicles were concentrated in three different areas within cells: cytoplasmatic pools in the Golgi region (Fig. 4A), small pools close to the plasmatic membrane of the cell body (Fig. 4B), and large pools stored in the projections of the cells (Fig. 4C). This distribution of vesicles is consistent with previous descriptions (34). Quantitative analysis showed three classes of positive vesicles in steady state conditions (Fig. 4E). One class of vesicles was positive for anti-pYE27 antibody and represented 27.2 ± 2.1% of the total positive vesicles. Another class was positive for anti-pYE17 antibody and represented 39.5 ± 4.8% of the total positive vesicles. A third population of vesicles was positive for both antibodies and represented 33.3 ± 3.1% of the total positive vesicles. Mean percentages were obtained for the total number of vesicles because results were not dependent on the location of the pools. The diameter of positive vesicles for anti-pYE27 alone, for anti-pYE17 alone, and for both antibodies were 106.3 ± 3.2, 113.0 ± 2.3, and
Initial Cleavage of Pro-TRH Is Key for Differential Sorting of N- and C-terminal Pro-TRH-derived Peptides—Using transfected AtT20 cells, we demonstrated earlier that pro-TRH still undergoes processing when the initial pro-TRH cleavage by PC1/3 is compromised, but the peptides products are not efficiently sorted to SGs (22). Therefore, the question was whether this initial cleavage determines the differential sorting of pro-TRH-derived peptides. First, we determined the N- and C-terminal pro-TRH-derived peptides produced by this mutant. Analysis by RIA of HPLC samples revealed that N- and C-terminal pro-TRH peptides were fully processed in a manner similar to that seen for the wild type pro-TRH (Fig. 5, A–D, compare with Fig. 2, A–D). Absolute moles of peptide secreted under each treatment are summarized in Table 2, and -fold stimulation responses are shown in Fig. 5. The amount of N-terminal peptides in the cell content was higher than for C-terminal peptides (97.0 ± 10.1 versus 50.2 ± 5.4 fmol/mg of protein, respectively, p < 0.05). Basal secretion for N-terminal peptides was also higher than C-terminal peptides (197.8 ± 19.3 versus 67.7 ± 5.9 fmol/ml, respectively, p < 0.05). NE failed to induce pro-TRH-derived peptide secretion. Under KCl (56 mM) treatment, secretion of N- and C-terminal peptides was 257.9 ± 45.0 and 91.7 ± 14.8 fmol/ml, respectively. Consequently, the -fold stimulation levels for N- and C-terminal pro-TRH-derived peptides were 1.30 ± 0.23 versus 1.35 ± 0.22, respectively (Fig. 5F). SI for N- and C-terminal peptides was 0.13 ± 0.05 and 0.02 ± 0.16, respectively, suggesting that they were not efficiently sorted to SGs (Table 2).

Using the same experimental conditions described above, we found that in AtT20 cells expressing PC1/3-block pro-TRH, the number of positive vesicles represented 49.0 ± 7.7% per cell per section. This percentage was similar to the value observed in cells expressing wild type pro-TRH, suggesting that results were not affected by a detection problem. These cells had the same three

143.7 ± 4.9 nm, respectively. The diameter of double-positive vesicles was greater than the diameter of vesicle containing one peptide (p < 0.05).

**FIGURE 4.** N- and C-terminal end products of pro-TRH processing are targeted to different vesicles in stably transfected AtT20 cells. Cells were fixed with 4% paraformaldehyde/0.15% glutaraldehyde solution and labeled with anti-pYE17 (visualized with 10-nm gold particle secondary antibody) followed by anti-pYE27 (visualized with 6- or 25-nm gold particle secondary antibody). A–C show 10/25-nm gold particle co-staining, and D shows 10/6-nm gold particle co-staining. Positive vesicles were concentrated in three different areas within cells: cytoplasmatic pools in the Golgi region (A), small pools close to the plasmatic membrane of the cell body (B), and large pools stored in the projections of the cells (C). A–D, insets, the corresponding low magnification pictures. Images show three classes of positive vesicles for either anti-pYE27 alone (arrowheads), anti-pYE17 alone (needles), or a combination of both antibodies (arrows). E, quantitative results obtained from sections labeled first with anti-pYE17 (10-nm gold particles) and then with anti-pYE27 (25-nm gold particles). Mean percentages represent the proportion of a particular positive vesicle compared with the total number of positive vesicles observed per micrograph, independently of the location of the pool.
Sorting and Secretion of Pro-TRH-derived Peptides

FIGURE 5. AtT20 cells stably transfected with PC1/3-block prepro-TRH cDNA produce the same N- and C-terminal pro-TRH-derived peptides; however, they are sorted to the constitutive pathway. Medium and cell content of AtT20 cells expressing PC1/3-Block pro-TRH under basal or KCl (56 mM) treatment were collected and subjected to HPLC purification, and fractions were analyzed using pYE27 and pYE17 RIAs. A–D, the upper panels show the results of medium samples analyzed with pYE27 (A) or pYE17 (B) RIAs; the middle panels show the results of cell content samples analyzed with pYE27 (C) or pYE17 (D) RIAs. E, -fold stimulation for both peptides calculated as total molar amount of peptide in stimulated media/molar amount of peptide in basal media. Data are presented as mean ± S.E.

TABLE 2
Secretion of N- and C-terminal pro-TRH-derived peptides by AtT20 cells stably transfected with PC1/3-block prepro-TRH cDNA

The first two columns of values show peptides released after 1 h of treatment with the different secretagogues. They are expressed as the total fmol of N- or C-terminal pro-TRH-derived peptides per ml of medium. Both peptides were measured by RIA. SI was calculated as indicated in the text.

<table>
<thead>
<tr>
<th>Secretagogue</th>
<th>Pro-TRH-derived peptides in medium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N-terminal</td>
</tr>
<tr>
<td>Basal</td>
<td>179.8 ± 19.3</td>
</tr>
<tr>
<td>KCl (56 mM)</td>
<td>257.9 ± 45.0</td>
</tr>
<tr>
<td>SI</td>
<td>0.13 ± 0.05</td>
</tr>
</tbody>
</table>

a p < 0.05 vs. total fmol of N-terminal pro-TRH-derived peptides.

classes of immunoreactive vesicles, distributed in the same type pools, as seen in cells expressing wild type pro-TRH (Fig. 6, A–D). However, the relative percentages were different. For the mutant, 0.9 ± 0.4 and 15.3 ± 1.9% of total positive vesicles were positive for anti-pYE27 and anti-pYE17 antibodies, respectively (p < 0.05 versus cells expressing wild type pro-TRH; Fig. 6E). In contrast, 81.7 ± 7.4% of total positive vesicles were positive for both antibodies (p < 0.05 versus cells expressing wild type pro-TRH; Fig. 6E). The diameter of positive vesicles for anti-pYE27 alone, for anti-pYE17 alone, and for both antibodies was 111.6 ± 4.4, 117.2 ± 3.0, and 160.2 ± 7.9 nm, respectively. The diameter of double-positive vesicles was greater than the diameter of vesicles containing only one peptide (p < 0.05), similar to results seen in cells expressing wild type pro-TRH. These results suggest that differential sorting of pro-TRH-derived peptides is affected when pro-TRH is not efficiently processed at the TGN level.

N- and C-terminal Pro-TRH-derived Peptides Are Differentially Packed and Secreted in Vivo—To establish the relevance of differential sorting in vivo, we studied the distribution of N- and C-terminal peptides in the hypothalamic ME, where axon terminals derived from the hypothalamic paraventricular nucleus release pro-TRH-derived peptides to the circulation. The data showed that ME contains and secretes the same peptides found in transfected AtT20 cells (Fig. 7, compare with Fig. 2, A–D). Absolute moles of peptide secreted under each treatment are summarized in Table 3, and -fold simulation responses are shown in Fig. 7. Basal secretion for N-terminal peptides was higher than for C-terminal peptides (89.0 ± 3.8 versus 39.1 ± 1.0 fmol/ml, respectively, p < 0.05), and the ratio between N- and C-terminal peptides was 2.28 ± 0.12. Treatment with NE (500 nM) increased C-terminal peptide release to 54.7 ± 2.2 fmol/ml (1.40 ± 0.06-fold, p < 0.05 versus basal), but secretion of N-terminal peptides was not affected (86.6 ± 2.4 fmol/ml). Under these experimental conditions hypothalamic explants showed a modest response to NE, which is consistent with an earlier report using similar system (35). KCl increased N- and C-terminal peptide release rates to 160.9 ± 9.1 and 122.6 ± 10.3 fmol/ml, respectively (p < 0.05 versus basal). However, KCl-induced stimulation was differential, because it increased more secretion of C-terminal than N-terminal peptides (3.14 ± 0.26-fold versus 1.81 ± 0.10-fold, respectively; Fig. 7, Table 3, p < 0.05). The SI parameter was higher for C- than for N-terminal pro-TRH-
We then determined the distribution of N- and C-terminal pro-TRH-derived peptides within the ME using an IEM approach. Under Karnovsky's fixative the ultrastructure of tissue was well preserved. In the external layer of the ME, we observed different classes of vesicles: small, small dense core, and large dense core vesicles. However, antibodies failed to label them (Fig. 8A). Therefore, we used a 4% paraformaldehyde/0.15% glutaraldehyde solution, which maintained antigenicity, although the ultrastructure was not as well preserved. Under these conditions, staining was seen in large dense core vesicles typically arranged in clusters within the axons (Fig. 8, B–D). In the ME, 15.3 ± 4.2% of the vesicle clusters exhibited antibody binding, and both species of colloidal gold-tagged antibodies were found in all of the stained clusters. In the ME, the diameter of positive dense core vesicles for anti-pYE27, for anti-pYE17, and for both antibodies was 69.1 ± 3.2, 73.0 ± 3.6, and 72.7 ± 2.7 nm, respectively. Quantitative analysis showed three classes of immunoreactive vesicles (Fig. 8E). One class was positive for anti-pYE27 and represented 33.4 ± 3.3% of the total positive vesicles. Another class was positive for anti-pYE17 and represented 44.3 ± 3.1% of the total positive vesicles. A third population of vesicles was positive for both antibodies and represented 22.2 ± 2.3% of the total positive vesicles.

**DISCUSSION**

This is the first study showing that a mammalian prohormone such as pro-TRH, initially cleaved in the TGN by PC1/3, can deliver its products to different vesicles of the secretory pathway. This is supported by the fact that N- and C-terminal pro-TRH-derived peptides are differentially secreted under specific and unspecific secretagogue stimulation and by the evidence of distinct distribution of peptides within the secretory vesicles. Furthermore, obliteration of the initial cleavage by PC1/3 on pro-TRH was shown to be critical in the targeting of N- and C-
terminal peptides to different vesicles. This could represent an essential mechanism for independent regulation of the secretion of different bioactive peptides derived from the same prohormone.

Synthesis of prohormone polypeptides and their processing to end products occur while they are sorted to the SGs (1–4). The correct sorting events of proteins and peptides to their target organelles are of fundamental importance in cell biology. However, identification of the signals or physical properties that ensure proper intracellular sorting of peptides to dense core SGs is not yet fully established. In a recent review article, Dikeakos and Reudelhuber (36) subdivided the targeting function of proteins that are sorted to SGs into three groups: membrane-associated (or traversing) tethers, tether-associated cargo, and aggregation. The enzyme PC1/3 is a granule-tethered protein that may act as a sorting chaperone for its substrates in addition to being a processing enzyme. In the case of pro-TRH, we recently showed that initial processing action of PC1/3 on pro-TRH, and not a cargo-receptor relationship, is important for the sorting of the pro-TRH-derived peptides (22). Thus, it is possible that key paired basic amino acids of pro-TRH (residues 107, 108, 113, 114, 152, 153, and 159), which constitute a cleavage site for PC1/3, would also function as granule sorting domains (22, 36).

Our results show that some N- and C-terminal pro-TRH-derived fragments behave independently after the prohormone is cleaved. It is possible that the initial cleavage changes the folding conformation and/or exposes different motifs that allow N- and C-terminal pro-TRH-fragments to aggregate independently or to interact with different components of the RSP. Interestingly, the differential sorting is independent of the cell type. This suggests that the N- and C-terminal ends of pro-TRH have conserved properties, which are sufficient for the sorting events. This also suggests that the cellular environment is not a critical factor, although the presence of RSP machinery should be necessary. Peptides derived from the same precursor, which are differentially packaged, have been shown for the egg-laying hormone (ELH) precursor in both *Aplysia californica* and *Lymnaea stagnalis* (37–39), but this phenomenon had never been demonstrated in mammalian prohormones.

TABLE 3
**Secretion of N- and C-terminal pro-TRH-derived peptides by hypothalamic explants**

The first two columns of values show peptides released after 1 h of treatment with the different secretagogues. They are expressed as the total fmol of N- or C-terminal pro-TRH-derived peptides per ml of medium. Both peptides were measured by RIA. SI was calculated as indicated in the text.

<table>
<thead>
<tr>
<th>Secretagogue</th>
<th>Pro-TRH-derived peptides in medium</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N-terminal</td>
<td>C-terminal</td>
</tr>
<tr>
<td></td>
<td>fmol/ml</td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>89.0 ± 3.8</td>
<td>39.1 ± 1.0*</td>
</tr>
<tr>
<td>NE (50 nM)</td>
<td>86.3 ± 4.9</td>
<td>48.2 ± 2.4**</td>
</tr>
<tr>
<td>NE (500 nM)</td>
<td>86.6 ± 2.4</td>
<td>54.7 ± 2.2**</td>
</tr>
<tr>
<td>KCl (56 mM)</td>
<td>160.9 ± 9.1b</td>
<td>122.6 ± 10.3**</td>
</tr>
<tr>
<td>SI</td>
<td>1.09 ± 0.14</td>
<td>2.74 ± 0.43*</td>
</tr>
</tbody>
</table>

*p < 0.05 vs. total fmol of N-terminal pro-TRH-derived peptides.

**p < 0.05 vs. basal.

*p < 0.05 vs. SI of N-terminal pro-TRH-derived peptides.

Our results show that some N- and C-terminal pro-TRH-derived fragments behave independently after the prohormone is cleaved. It is possible that the initial cleavage changes the folding conformation and/or exposes different motifs that allow N- and C-terminal pro-TRH-fragments to aggregate independently or to interact with different components of the RSP. Interestingly, the differential sorting is independent of the cell type. This suggests that the N- and C-terminal ends of pro-TRH have conserved properties, which are sufficient for the sorting events. This also suggests that the cellular environment is not a critical factor, although the presence of RSP machinery should be necessary. Peptides derived from the same precursor, which are differentially packaged, have been shown for the egg-laying hormone (ELH) precursor in both *Aplysia californica* and *Lymnaea stagnalis* (37–39), but this phenomenon had never been demonstrated in mammalian prohormones.

**FIGURE 7.** NE and KCl induce a differential release of N- versus C-terminal pro-TRH-derived peptides in hypothalamic explants. Cell content and release of hypothalamic explants under basal, NE (50–500 nM), or KCl (56 mM) treatment were collected and subjected to HPLC purification, and fractions were analyzed using pYE27 and pYE17 RIAs. The upper panels show the results of basal and KCl-stimulated medium samples analyzed with pYE27 (A) or pYE17 (B) RIAs; the middle panels show the results of basal and KCl-stimulated cell content samples analyzed with pYE27 (C) or pYE17 (D) RIAs. E, fold stimulation for both peptides calculated as total molar amount of peptide in stimulated media/molar amount of peptide in basal media. Data are presented as mean ± S.E. a, p < 0.05 versus own basal release. b, p < 0.05 versus -fold stimulation of N-terminal pro-TRH-derived peptide for the same stimulus.
Pro-TRH producing cells contain a significant number of vesicles that store both N- and C-terminal pro-TRH-derived peptides. However, most of the pro-TRH molecules are initially cleaved in the TGN (21). Thus, it is possible that double-positive vesicles are heterogeneous in their quantitative content, enriched with one peptide but also containing small amounts of other pro-TRH-derived peptides. This possibility fits better with our quantitative release data, which show that N-terminal peptides are highly secreted under basal condition but also are secreted upon stimulation. It has been already shown that SG populations are heterogeneous in their quantitative content of proteins derived from different genes (40), but whether this can also occur with two peptides derived from the same precursor requires further demonstration. Double IEM has been used to quantify the relative content in double-positive vesicles (41, 42); however, there are serious objections to this usage because of steric hindrance problems and differences in labeling efficiency between gold probes of different sizes (33). Interestingly, double-positive vesicles in transfected cells were larger than vesicles containing one peptide. This observation may suggest that double-positive vesicles belong to the group of immature vesicles, but this hypothesis needs to be confirmed. The finding that the molar ratio of N- to C-terminal pro-TRH-derived peptides under steady state conditions was higher than 1 was unexpected based on the biosynthetic pathway of Fig. 1. These peptides are not significantly degraded, either intra- nor extracellularly, as suggested by the fact that bafilomycin A1, an inhibitor of the lysosomal degradation, did not improve the molar ratio and that these synthetic peptides added to the medium were stable in the presence of cells (not shown). Thus, we speculate that this molar ratio is a consequence of the fact that N-terminal intermediate forms are more rapidly processed than C-terminal ones, as we demonstrated using pulse-chase strategies (21). Still, this intriguing observation, which requires further investigation, does not invalidate the differences in -fold stimulation that support the differential secretion.

Secretory cells release peptide content in the SGs upon stimulation. Potassium is an unspecific secretagogue that induces peptide release based on its ability to depolarize cells and

FIGURE 8. N- and C-terminal end products of pro-TRH are partially located in different vesicles within the ME fibers. Sprague-Dawley rats were perfused with Karnovsky’s fixative (A, inset, shows a panoramic micrograph of this region) or with 4% paraformaldehyde/0.15% glutaraldehyde in PBS (B–D). C and D show an increased magnification of B. Images show three classes of positive vesicles for anti-pYE17 antibody alone (arrowheads), anti-pYE17 antibody alone (needles), or a combination of both antibodies (arrows). E, quantitative results obtained from sections labeled first with anti-pYE17 (10-nm gold particles) and then with anti-pYE27 (25-nm gold particles). Mean percentages represent the proportion of a particular positive vesicle compared with the total number of positive vesicles observed per micrograph.
Sorting and Secretion of Pro-TRH-derived Peptides

increase cytosolic Ca\(^{2+}\) (28). NE is a physiological secretagogue that acts via specific receptors using protein kinase A and Ca\(^{2+}\) -dependent intracellular pathways in both neurons and AtT20 cells (35, 43). The secretion of N-terminal peptides was only slightly increased by NE and KCl, suggesting that this peptide is not efficiently stored in secretory vesicles (Figs. 2 and Fig. 7). In contrast, both secretagogues strongly secreted the C-terminal pro-TRH-derived peptides, indicating that these peptides are preferentially stored into SGs. The high SI for the C-terminal peptide quantitatively supports this conclusion (Tables 1 and 3). Recently, we showed that initial processing of pro-TRH by PC1/3 in the TGN is necessary for the correct trafficking of pro-TRH-derived peptides to secretory vesicles (22), and we now show that initial cleavage of pro-TRH in the TGN is also critical for the sorting of N- and C-terminal peptides to different vesicles. Interestingly, PC1/3-block pro-TRH produces the same final N- and C-terminal pro-TRH-derived peptides, but they are constitutively released (SI close to zero), probably because the mutated prohormone is cleaved in a post-TGN compartment (22). Thus, our results suggest that the differential secretion of pro-TRH-related peptides is due to the early processing in the TGN that governs its differential storage, most likely because C-terminal pro-TRH-derived peptides behave independently and can be more efficiently sorted to the RSP than the N-terminal ones.

The pro-TRH sequence contains five copies of the TRH pro-genitor and another seven pro-TRH-derived peptides, which can be further processed (17, 18). For instance, proprepro-TRH-(178–199) peptide is cleaved to give prepro-TRH-(178–184) and prepro-TRH-(186–199) peptides. In this study, we found that ME stores the C-terminal prepro-TRH-(208–255) peptide; however, the main product released is a shorter peptide, prepro-TRH-(241–255). This peptide is likely derived from the cleavage of prepro-TRH-(208–255) at the C-terminal side of the lysine residue at prepro-TRH-(240), which follows the rules that govern monobasic cleavage sites (44). Importantly, we have recently shown that this N-terminal peptide is produced abundantly in the lateral hypothalamus (45). However, its physiological relevance remains unknown. The N-terminal propro-TRH-derived peptide is also intriguing because it is stored as one variant of the N-terminal propro-TRH-(25–50) (2759 Da) but is released as two different variant (2755 and 2759 Da). We have evidence that the N-terminal segment, prepro-TRH-(25–50), plays a conformational role in the initial folding of the pro-TRH3; this possibility is consistent with its constitutive release. However, the significance of these late and undetermined post-transcriptional modifications remains unknown. For other prohormones the same mechanism of differential sorting may occur. For instance, proghrelin generates two peptide hormones with antagonist actions: ghrelin increases food intake and body weight, whereas obestatin has the opposite action (46, 47). Similarly, pro-opiomelanocortin (POMC) produces two POMC-derived peptides, α-melanocyte-stimulating hormone and opioids, which have opposite actions on body weight and appetite (48–50). In conclusion, here we have demonstrated that peptides derived from the N- and C-terminal sides of pro-TRH can be differentially sorted and secreted. This is a novel aspect of the biology of pro-TRH that also may have important implications for the study of other prohormones.

Acknowledgments—We thank Carol Ayala and Virginia Hovanesian for assistance in the generation of IEM and presentation of the images.

REFERENCES

Prothyrotropin-releasing Hormone Targets Its Processing Products to Different Vesicles of the Secretory Pathway

Mario Perello, Ronald Stuart and Eduardo A. Nillni

doi: 10.1074/jbc.M800732200 originally published online May 12, 2008

Access the most updated version of this article at doi: 10.1074/jbc.M800732200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC’s e-mail alerts

This article cites 49 references, 18 of which can be accessed free at http://www.jbc.org/content/283/29/19936.full.html#ref-list-1